Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irofan
- Development stage
- Unknown
- Lead developer
- Apostle Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Irofan is an oral fixed-dose combination of ferrous ascorbate and folic acid developed and marketed by Apostle Remedies. It is formulated as a tablet and used as a nutritional supplement to treat and prevent iron deficiency and iron deficiency anaemia, particularly during pregnancy or periods of nutritional inadequacy. Ferrous ascorbate provides a highly bioavailable form of elemental iron that is essential for the synthesis of haemoglobin and efficient oxygen transport. Folic acid (vitamin B9) is a crucial nutrient that supports red blood cell formation, DNA synthesis, and cellular repair, as well as the proper development of the fetal brain and spinal cord.
- Brand names
- Irofan
- Other names
- ferrous ascorbate + folic acid
02
Targets
DHFR (Dihydrofolate reductase)SLC11A2 (DMT1)FOLR1 (FRα)
Beyond the preview
Go deeper on Irofan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irofan.